OBESITY EXPERT FORUM (OEF)

OBESITY ISSUES

Obesity poses one of the greatest public health challenges for the 21st century with particularly alarming trends in several parts of the world. The prevalence of adult obesity has risen three-fold in many countries since the 1980s and the epidemic is spreading at particularly high rates in children.

The management of Obesity and its related disorders is now at the forefront of Government and Public Health initiatives across the World. There is increasing concern within the European Union and the WHO about Obesity and its co-morbidities such as Type 2 Diabetes, Hypertension, Cardiovascular Disease and Cardiometabolic Risk and Prevention.

OBESITY EXPERT FORUM OBJECTIVES

The IASO Obesity Expert Forum aims to address these issues by creating a strategic platform for discussion between senior IASO members and invited senior industry representatives, from companies active in the field of obesity management, prevention and research, with a focus on:

Updating industry figures on important initiatives and achievements
Facilitating dialogue
Exchanging expertise on selected key issues facing all those involved in tackling obesity and its co-morbidities.

HOT TOPIC TO BE DISCUSSED

The focus will be on the reimbursement of obesity drugs.

Please refer to the full programme further below for more details

FORMAT

The OEF meeting takes the following format:

Update on latest IASO developments
Focussed discussion on a “Hot Topic”
Working lunch/Debate

The meeting will take place 08.00 – 14.00, Wednesday 28th October 2009, and will be held at the TOS Congress, Washington, US.

ATTENDANCE

Companies can attend this forum on an invitation only by IASO. This guarantees a small focus group with senior industrial representatives where confidential competitors’ practices can be exchanged.

Diabetes, Hypertension, Cardiovascular Disease and Cardiometabolic Risk and Prevention.

IASO WORLD EXPERTS

Each IASO Obesity Expert Forum will be hosted by two of IASO’s most senior members, Professor Arne Astrup and Professor Philip James.

Find out more about the Obesity Expert Forum hosts

PROGRAMME TO DATE

Chairperson

Professor Richard Atkinson (IASO North American Vice President)

08:00 Welcome and scene setting

Professor Philip James (IASO President)

• Why Obesity is a disease – Review of evidence to date

08:30 Overview of Public Health Policy – Why is action necessary in the field of obesity and chronic diseases

Professor Ken Thorpe (Emory University Department of Health Policy and Management)

• Why are chronic diseases important for public policy

• What are the trends and changes in the past five years

09:00 The economics and health care costs of obesity – analysis of how health care costs are changing in the USA

Paul Mango (McKinsey)

• Review the cost to society of obesity

• How does an aging obese population living with chronic diseases impact health costs

• What are the historic trends and future costs

09:30 Overview of the issues of obesity drugs, an aging population living with chronic diseases and the cost to a health insurer

Dr Scott Young (Associate Executive Director, Clinical Care and Innovation, The Permanente Federation and Co-Executive Director of Kaiser Permanente's Care Management Institute)

• How has obesity changed the provision of health insurance in the USA

• What are the future trends

10:00 Discussion

10:45 Coffee Break

11:30 Routes to regulatory approval for metabolic drugs

Professor David J Heal (Director RenaSci Consultancy, BioCity)

• Review the process of regulatory approval in the USA

• How are obesity drugs approved

• Has the CB1 class of drugs influenced the regulatory process

• What are the trends

• How has this changed in the past 5 years

12:00 How reimbursement affects the research and development of obesity drugs – A perspective from the pharmaceutical industry

Dr Janske Aarts (Pfizer)

• How does reimbursement alter the development of obesity drugs

• How has the industry reacted and what are the future developments

12:30 The reimbursement of obesity drugs – A perspective from the FDA

Dr Margaret A Hamburg (Commissioner of food and drugs FDA)

• What is the perspective from the FDA

• How will thinking develop in the next 5 years

13:00 Interactive Discussion

14:00 Close

BENEFITS

By attending an OEF meeting you will be entitled to:

Access to worldwide opinion leaders in the obesity field
Involvement in the selection of topics for future seminars
Increased exposure as your organisation will be acknowledged on the official IASO website and e-bulletins
A policy report which summarises the information exchanged during the OEF meeting
Opportunity to ask your questions to experts in the obesity field and make it interactive
Free membership access to “Obesity International” on the IASO website, a worldwide obesity data prevalence network.

YOUR DEDICATED CONTACT

IASO has appointed a dedicated person for the management of OEF attendees in order to build up a long term relationship across IASO’s diversified activities.

As part of this relationship and your commitment to an OEF meeting, you will be privileged for all negotiations across IASO conferences and congresses annual programmes. Tailored offers can be discussed on a one to one basis to define a suitable package for attending other IASO conferences and congresses.

Please contact us now to find out more about the Obesity Expert Forum and discuss in detail your interest and how we can tailor your attendance at this meeting.

To guarantee a high quality forum places are limited! Avoid any disappointment and contact us as soon as possible.

View current Obesity Expert Forum members

Please contact us for further information:

OBESITY EXPERT FORUM (OEF)

Estelle Challe

Tel: +44(0)20 7467 9618

Fax: +44(0)20 7636 9258

Email: echalle@iaso.org